Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Posted by Trevor Kearing on Mar 19th, 2026

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.92 and traded as low as $2.89. Cryo-Cell International shares last traded at $2.94, with a volume of 16,518 shares.

Cryo-Cell International Stock Performance

The company has a fifty day simple moving average of $3.34 and a two-hundred day simple moving average of $3.91. The stock has a market capitalization of $25.71 million, a price-to-earnings ratio of -10.29 and a beta of 0.55.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last released its earnings results on Friday, February 27th. The company reported ($0.47) earnings per share (EPS) for the quarter. The firm had revenue of $7.84 million during the quarter.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 10.44% of the company’s stock.

About Cryo-Cell International

(Get Free Report)

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.